Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company previously committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Our vision was to become a leader in the nephrology and specialty care space by delivering innovative therapeutic offerings to patients and healthcare providers before a nationwide voluntary recall of OMONTYS® (peginesatide) Injection in February 2013. In March 2013 Affymax commenced a review of strategic alternatives.